Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    86
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA02 LADININ G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 572,393 L.L
L01EF01 PALBRANCE 125 G Palbociclib - 125mg 125mg Capsule 69,032,469 L.L
M01AE01 CAPTAIN FORTE G Ibuprofen - 400mg 400mg Capsule, soft gelatin 508,740 L.L
N02AJ08 ASTEFOR G Ibuprofen - 400mg, Codeine phosphate hemihydrate - 30mg Tablet, film coated 935,314 L.L
N03AX16 NEUREXAL G Pregabalin - 25mg 25mg Capsule 321,754 L.L
N06AB06 RESTRALINE G Sertraline HCl - 50mg 50mg Tablet, film coated 575,933 L.L
R01BA52 ORADUS P G Pseudoephedrine sulfate - 120mg, Desloratadine - 2.5mg Tablet, extended release 746,153 L.L
R06AX13 CLARA G Loratadine (micronised) - 5mg/5ml 5mg/5ml Syrup 215,015 L.L
A02BC01 STOMAZOLE G Omeprazole - 20mg 20mg Capsule 15,757,784 L.L
A07EC02 SALCROZINE G Mesalazine - 500mg 500mg Tablet, gastroresistant 2,013,076 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 170,630 L.L
C03CA01 FUROSEMIDE SALF G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 216,359 L.L
C09CA03 VIOSTAN 80 G Valsartan - 80mg 80mg Tablet, film coated 526,786 L.L
C10AA05 ATORLIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,484,626 L.L
G04BE08 LINK G Tadalafil - 20mg 20mg Tablet, film coated 1,374,751 L.L
J01CR02 POSMOX G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Powder 616,824 L.L
J01MA02 SUPERFLOX G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 458,250 L.L
L01EF01 PAPILLIO G Palbociclib - 125mg 125mg Capsule, hard 147,883,080 L.L
M01AE01 IBUPROFEN B. BRAUN G Ibuprofen - 200mg/50ml 200mg/50ml Injectable solution 161,261 L.L
N03AX16 PLENICA G Pregabalin - 25mg 25mg Capsule 697,454 L.L
N06AB06 SERTINE G Sertraline HCl - 50mg 50mg Tablet, scored 520,899 L.L
R01BA52 ORADUS P G Pseudoephedrine sulfate - 120mg, Desloratadine - 2.5mg Tablet, extended release 255,970 L.L
R06AX13 LORINE G Loratadine (micronised) - 5mg/5ml 5mg/5ml Syrup 215,015 L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet L.L
A02BC01 GASTRIMUT G Omeprazole - 40mg 40mg Capsule, hard, gastro-resistant 503,941 L.L
A10BK03 EMPAZA G Empagliflozin - 25mg 25mg Tablet, film coated 1,740,724 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 182,720 L.L
C03CA01 LASIMIDE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,300,328 L.L
C10AA05 ATORVA TAD G Atorvastatin - 40mg 40mg Tablet, film coated 1,405,659 L.L
D07XC01 BETA-MICOTER G Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 415,951 L.L
    ...
    86
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025